CHRISTY FULLER: Open Payments
NPI 1346801883 · LINCOLN, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$972 in 49 payments from 15 companies in 2025. Trend: 2023 $898 · 2024 $399 · 2025 $972
Food & beverage: $972
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 16 | $304 |
| AstraZeneca Pharmaceuticals LP | 8 | $164 |
| Novo Nordisk Inc | 7 | $132 |
| Otsuka America Pharmaceutical, Inc. | 2 | $59 |
| GlaxoSmithKline, LLC. | 2 | $53 |
| Axsome Therapeutics, Inc. | 2 | $38 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $33 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $33 |
| Amgen Inc. | 2 | $31 |
| Dexcom, Inc. | 1 | $25 |
Products named: VRAYLAR, AIRSUPRA, BOTOX, Ozempic, REXULTI, UBRELVY, TRELEGY ELLIPTA, BREZTRI.
Industry payments across AL — which companies pay providers there.
